Weight-adapted fixed-dose combined adult antiretroviral tablets for HIV-infected children

Ferran  Bossacoma Busquets; Emilia Sánchez Ruiz; Antoni  Noguera-Julián; Miquel  Villaronga Flaqué; Clàudia Fortuny

doi:10.1111/jcpt.13341

Weight-adapted fixed-dose combined adult antiretroviral tablets for HIV-infected children

Títol traduït de la contribució: Weight-adapted fixed-dose combined adult antiretroviral tablets for HIV-infected children

Ferran Bossacoma Busquets
, Emilia Sánchez Ruiz
, Antoni Noguera-Julián
, Miquel Villaronga Flaqué
, Clàudia Fortuny

Facultat de Ciències de la Salut Blanquerna

Producció científica: Article en revista indexada › Article › Avaluat per experts

1 Citació (Scopus)

Resum

What is known and objective:Therapeutic alternatives to simplify antiretroviral therapy (ART) in HIV-infected children are needed. We report our experience with abacavir(ABC)/lamivudine(3TC) individualized dose compounded capsules (IDCC).

Comment: We present a prospective case series of HIV-infected children who did not weigh enough to receive the adult fixed-dose combination including ABC/3TC 600mg/300mg, and were treated with weight-adapted ABC/3TC IDCC in Barcelona, Spain. Thirteen patients (12 girls) received ABC/3TC IDCC for a median(IQR) time of 30(17-54) months. No significant changes were observed in CD4 cell counts, weight or height z-scores over time. Suppression of viral replication was maintained in 7 patients with undetectable viremia at baseline. Another 5 patients achieved viral suppression with ABC/3TC IDCC-based ART, while one non-adherent girl did not. No adverse events related to ABC/3TC IDCC were observed.

What is new and conclusion: Despite small numbers, the long-term use of ABC/3TC IDCC was feasible, safe, and effective in the treatment of HIV-infected children.

Títol traduït de la contribució	Weight-adapted fixed-dose combined adult antiretroviral tablets for HIV-infected children
Idioma original	Anglès
Pàgines (de-a)	867-871
Nombre de pàgines	5
Revista	J Clin Pharm Ther
DOIs	https://doi.org/10.1111/jcpt.13341
Estat de la publicació	Publicada - 4 de gen. 2021

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

ODS 3 Salut i benestar

Accés al document

10.1111/jcpt.13341Llicència: Sense especificar

Com citar-ho

@article{f2dbd46903ee47e0aef61d4409ab10f4,

title = "Weight-adapted fixed-dose combined adult antiretroviral tablets for HIV-infected children",

abstract = "What is known and objective:Therapeutic alternatives to simplify antiretroviral therapy (ART) in HIV-infected children are needed. We report our experience with abacavir(ABC)/lamivudine(3TC) individualized dose compounded capsules (IDCC). Comment: We present a prospective case series of HIV-infected children who did not weigh enough to receive the adult fixed-dose combination including ABC/3TC 600mg/300mg, and were treated with weight-adapted ABC/3TC IDCC in Barcelona, Spain. Thirteen patients (12 girls) received ABC/3TC IDCC for a median(IQR) time of 30(17-54) months. No significant changes were observed in CD4 cell counts, weight or height z-scores over time. Suppression of viral replication was maintained in 7 patients with undetectable viremia at baseline. Another 5 patients achieved viral suppression with ABC/3TC IDCC-based ART, while one non-adherent girl did not. No adverse events related to ABC/3TC IDCC were observed. What is new and conclusion: Despite small numbers, the long-term use of ABC/3TC IDCC was feasible, safe, and effective in the treatment of HIV-infected children.",

author = "\{Bossacoma Busquets\}, Ferran and \{S{\'a}nchez Ruiz\}, Emilia and Antoni Noguera-Juli{\'a}n and \{Villaronga Flaqu{\'e}\}, Miquel and Cl{\`a}udia Fortuny",

note = "Bossacoma Busquets F; S{\'a}nchez E; Noguera-Julian A; Villaronga Flaqu{\'e} M; Fortuny C",

year = "2021",

month = jan,

day = "4",

doi = "10.1111/jcpt.13341",

language = "English",

pages = "867--871",

journal = "J Clin Pharm Ther",

issn = "1365-2710",

publisher = "John Wiley and Sons Inc",

}

TY - JOUR

T1 - Weight-adapted fixed-dose combined adult antiretroviral tablets for HIV-infected children

AU - Bossacoma Busquets, Ferran

AU - Sánchez Ruiz, Emilia

AU - Noguera-Julián, Antoni

AU - Villaronga Flaqué, Miquel

AU - Fortuny, Clàudia

N1 - Bossacoma Busquets F; Sánchez E; Noguera-Julian A; Villaronga Flaqué M; Fortuny C

PY - 2021/1/4

Y1 - 2021/1/4

N2 - What is known and objective:Therapeutic alternatives to simplify antiretroviral therapy (ART) in HIV-infected children are needed. We report our experience with abacavir(ABC)/lamivudine(3TC) individualized dose compounded capsules (IDCC). Comment: We present a prospective case series of HIV-infected children who did not weigh enough to receive the adult fixed-dose combination including ABC/3TC 600mg/300mg, and were treated with weight-adapted ABC/3TC IDCC in Barcelona, Spain. Thirteen patients (12 girls) received ABC/3TC IDCC for a median(IQR) time of 30(17-54) months. No significant changes were observed in CD4 cell counts, weight or height z-scores over time. Suppression of viral replication was maintained in 7 patients with undetectable viremia at baseline. Another 5 patients achieved viral suppression with ABC/3TC IDCC-based ART, while one non-adherent girl did not. No adverse events related to ABC/3TC IDCC were observed. What is new and conclusion: Despite small numbers, the long-term use of ABC/3TC IDCC was feasible, safe, and effective in the treatment of HIV-infected children.

AB - What is known and objective:Therapeutic alternatives to simplify antiretroviral therapy (ART) in HIV-infected children are needed. We report our experience with abacavir(ABC)/lamivudine(3TC) individualized dose compounded capsules (IDCC). Comment: We present a prospective case series of HIV-infected children who did not weigh enough to receive the adult fixed-dose combination including ABC/3TC 600mg/300mg, and were treated with weight-adapted ABC/3TC IDCC in Barcelona, Spain. Thirteen patients (12 girls) received ABC/3TC IDCC for a median(IQR) time of 30(17-54) months. No significant changes were observed in CD4 cell counts, weight or height z-scores over time. Suppression of viral replication was maintained in 7 patients with undetectable viremia at baseline. Another 5 patients achieved viral suppression with ABC/3TC IDCC-based ART, while one non-adherent girl did not. No adverse events related to ABC/3TC IDCC were observed. What is new and conclusion: Despite small numbers, the long-term use of ABC/3TC IDCC was feasible, safe, and effective in the treatment of HIV-infected children.

U2 - 10.1111/jcpt.13341

DO - 10.1111/jcpt.13341

M3 - Article

SN - 1365-2710

SP - 867

EP - 871

JO - J Clin Pharm Ther

JF - J Clin Pharm Ther

ER -

Weight-adapted fixed-dose combined adult antiretroviral tablets for HIV-infected children

Resum

SDG de les Nacions Unides

Accés al document

Fingerprint

Com citar-ho